+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Whole Exome Sequencing [WES] Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 173 Pages
  • February 2024
  • Infogence Global Research
  • ID: 5650853

The high demand for personalized medicine and development of new innovative products by key players provide numerous opportunities for market expansion in the near future

The Global Whole Exome Sequencing [WES] Market is estimated to be USD 1.22 Bn in 2023 and is expected to reach USD 3.31 Bn by 2028 growing at a CAGR of 22.13%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Whole Exome Sequencing [WES] Market is segmented based on Products and Services, Technology, Applications, End User, and Geography.
  • By Products and Services, the market is classified into Systems, Kits, and Services.
  • By Technology, the market is classified into Sequencing By Synthesis (SBS), ION Semiconductor Sequencing, and Other Technologies.
  • By Applications, the market is classified into Diagnostics, Drug Discovery and Development, Personalized Medicine, and Agriculture & Animal Research.
  • By End User, the market is classified into Research Centers and Academic & Government Institutes, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Agilent Technologies, Inc., Ambry Genetics, Beckman Coulter Inc., BGI Genomics Co., Ltd., BIONEER Corp., Bio-Rad Laboratories, Inc., CD Genomics, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Whole Exome Sequencing [WES] Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Whole Exome Sequencing [WES] Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Whole Exome Sequencing [WES] Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 The Low Cost and High Speed of the WES Technology
4.1.2 Increasing Number of New Scientific Applications to Fuel the Market Growth
4.1.3 Cost-effective Compared to Other Sequencing Methods
4.2 Restraints
4.2.1 Need for Skilled Professionals
4.2.2 Unfavorable Regulatory Policies
4.2.3 Ethical and Legal Issues Related to Whole Exome Sequencing
4.3 Opportunities
4.3.1 Personalized Medicine to Fuel the Demand for WES Technology
4.3.2 Alliances Amongst Leading Research Institutes to Increase Drug Discovery
4.4 Challenges
4.4.1 High Complexity of Technique
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Whole Exome Sequencing [WES] Market, By Products and Services
6.1 Introduction
6.2 Systems
6.2.1 HiSeq Series
6.2.2 MiSeq
6.2.3 ION Torrent Platform
6.3 Kits
6.3.1 DNA Fragmentation
6.3.2 Library Preparation Kits
6.3.3 Target Enrichment Kits
6.4 Services
6.4.1 Sequencing Services Market
6.4.2 Data Analysis (Bioinformatics) Services
7 Global Whole Exome Sequencing [WES] Market, By Technology
7.1 Introduction
7.2 Sequencing By Synthesis (SBS)
7.3 ION Semiconductor Sequencing
7.4 Other Technologies
8 Global Whole Exome Sequencing [WES] Market, By Applications
8.1 Introduction
8.2 Diagnostics
8.2.1 Cancer Diagnostics
8.2.2 Monogenic (Mendelian) Disorders
8.2.3 Monogenic Types of Diabetes
8.3 Drug Discovery and Development
8.4 Personalized Medicine
8.5 Agriculture & Animal Research
9 Global Whole Exome Sequencing [WES] Market, By End User
9.1 Introduction
9.2 Research Centers and Academic & Government Institutes
9.3 Hospitals and Clinics
9.4 Pharmaceutical & Biotechnology Companies
9.5 Others
10 Americas’ Whole Exome Sequencing [WES] Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas
11 Europe’s Whole Exome Sequencing [WES] Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Italy
11.9 Netherlands
11.10 Norway
11.11 Poland
11.12 Russia
11.13 Spain
11.14 Sweden
11.15 Switzerland
11.16 United Kingdom
11.17 Rest of Europe
12 Middle East and Africa’s Whole Exome Sequencing [WES] Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Qatar
12.5 Saudi Arabia
12.6 South Africa
12.7 United Arab Emirates
12.8 Rest of MEA
13 APAC’s Whole Exome Sequencing [WES] Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific
14 Competitive Landscape
14.1 Competitive Quadrant
14.2 Market Share Analysis
14.3 Strategic Initiatives
14.3.1 M&A and Investments
14.3.2 Partnerships and Collaborations
14.3.3 Product Developments and Improvements
15 Company Profiles
15.1 Agilent Technologies, Inc.
15.2 Ambry Genetics
15.3 Beckman Coulter Inc.
15.4 BGI Genomics Co., Ltd.
15.5 BIONEER Corp.
15.6 Bio-Rad Laboratories, Inc.
15.7 CD Genomics
15.8 CEGAT GmbH
15.9 Eurofins Genomics, Inc.
15.10 GeneDx, LLC
15.11 Genewiz, Inc.
15.12 Illumina, Inc.
15.13 Integragen SA
15.14 Integrated DNA Technologies, Inc.
15.15 Macrogen, Inc.
15.16 Pacific Biosciences of California, Inc.
15.17 PerkinElmer Genomics
15.18 Roche NimbleGen, Inc.
15.19 Sengenics Corporation LLC
15.20 Thermo Fisher Scientific, Inc.
16 Appendix
16.1 Questionnaire

Companies Mentioned

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Beckman Coulter Inc.
  • BGI Genomics Co., Ltd.
  • BIONEER Corp.
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • CEGAT GmbH
  • Eurofins Genomics, Inc.
  • GeneDx, LLC
  • Genewiz, Inc.
  • Illumina, Inc.
  • Integragen SA
  • Integrated DNA Technologies, Inc.
  • Macrogen, Inc.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer Genomics
  • Roche NimbleGen, Inc.
  • Sengenics Corporation LLC
  • Thermo Fisher Scientific, Inc.